Company: WHWK
Filing Date: 2025-03-31
Form Type: S-3
Source: 0001193125-25-068942
Chunk: 2

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-31
Form: S-3
Chunk 2
---
500 shares (the “Shares”) of common stock, par value $0.0001
per share, of Whitehawk Therapeutics, Inc. (f/k/a Aadi Bioscience, Inc.), a Delaware corporation (the “Company”), by the selling stockholders identified in this prospectus, including their transferees, pledgees or donees or their
respective successors (the “selling stockholders”), which Shares consist of 21,592,000 outstanding shares of our common stock held by the selling stockholders and 20,076,500 shares of our common stock issuable upon the exercise of
outstanding pre-funded warrants to purchase shares of our common stock held by the selling stockholders. Such securities were issued and sold to the selling stockholders in a private placement (the
“Private Placement”)pursuant to a subscription agreement among us and such selling stockholders dated December 19, 2024 (the “Subscription Agreement”). Concurrently with the closing of the Private
Placement, we entered into a registration rights agreement (the “Registration Rights Agreement”) with the selling stockholders, and we are registering the Shares being offered hereunder pursuant to such registration rights agreement
on behalf of the selling stockholders, to be offered and sold by them from time to time. We will not receive any proceeds from the sale of the Shares offered by this prospectus.

We have agreed, pursuant to the registration rights agreement, to bear all of the expenses incurred in connection with the registration of the Shares. The
selling stockholders will pay or assume discounts, commissions, fees of underwriters, selling brokers or dealer managers and similar expenses, if any, incurred for the sale of the Shares.

The selling stockholders identified in this prospectus may offer the Shares pursuant to this prospectus from time to time through public or private transactions
at fixed prices, at market prices prevailing at the time of sale, at prices related to prevailing market prices or at privately negotiated prices. The selling stockholders may sell shares to or through underwriters, broker-dealers or agents, who may
receive compensation in the form of discounts, concessions or commissions from the selling stockholders, the purchasers of the shares, or both. For additional information on the methods of sale that may be used by the selling stockholders, see the
section entitled “Plan of Distribution” on page 14. For a list of the selling stockholders, see the section entitled “Selling Stockholders” on page 9.

We may amend or supplement this